Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02821572

Acronym

PTI Fc

Enrollment

Registered

2016-07-01

Start date

2014-10-02

Completion date

2024-09-30

Last updated

2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Thrombocytopenia

Brief summary

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a peripheral destruction of platelets responsible for bleedings. Monocytes/macrophages play a double role by phagocyting platelets recognized by autoantibodies and by maintaining the autoimmune response via their antigen-presenting cell functions. Fcgamma receptors (FcγR), that are represented by activating receptors (FcγRI, FcγRIIa, FcγRIII) and an inhibiting one (FcγRIIb), are involved in the regulation of macrophages and have been reported to be dysregulated in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematous. The aim of this study is to compare the expression of FcγR in patients with ITP on circulating monocytes and on splenic macrophages.

Interventions

BIOLOGICALblood sample

PROCEDUREspleen sample

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

ITP group * Patients who have provided written consent * Patients over 18 years * Patients with national health insurance * Patients with ITP, defined as thrombocytopenia \< 100 G/L, after exclusion of infection- or drug-related thrombocytopenia and malignant hemopathy. Control Group * Persons who have provided a written consent * Persons over 18 years * Persons with national health insurance * Persons without autoimmune disease

Exclusion criteria

* Patients under guardianship * Pregnancy

Design outcomes

Primary

Measure	Time frame
1. The expressions of the activating FcγRs and the inhibiting receptor (FcγRIIb) on monocytes will be compared between ITP patients at diagnosis and controls - physiological parameter	through study completion, an average of 2 years

Secondary

Measure	Time frame
1. The expressions of the activating FcγRs and the inhibiting receptor (FcγRIIb) on splenic macrophages will be compared between ITP patients and controls. - physiological parameter	through study completion, an average of 2 years

Countries

France

Contacts

Primary ContactBernard BONNOTTE

bernard.bonnotte@chu-dijon.fr3.80.29.34.32

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026